ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.4612C>T (p.Gln1538Ter)

dbSNP: rs80356992
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000077579 SCV000300145 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Invitae RCV000048606 SCV000076619 pathogenic Hereditary breast ovarian cancer syndrome 2023-11-25 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Gln1538*) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with clinical features of hereditary breast and ovarian cancer syndrome (PMID: 9452076, 11920621, 25151137, 29446198, 29470806). This variant is also known as 4731C>T. ClinVar contains an entry for this variant (Variation ID: 55239). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000077579 SCV000326009 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2015-10-02 criteria provided, single submitter clinical testing
GeneDx RCV000420125 SCV000516967 pathogenic not provided 2023-09-28 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 4731C>T; This variant is associated with the following publications: (PMID: 21720365, 9452076, 11920621, 25525159, 26187060, 24578176, 25151137, 27221827, 19298662, 29339979, 30787465, 29470806, 31214711, 32410793, 29446198, 34917121, 30720243, 31825140, 30322717, 33948387)
Ambry Genetics RCV000510121 SCV000607974 pathogenic Hereditary cancer-predisposing syndrome 2021-12-21 criteria provided, single submitter clinical testing The p.Q1538* pathogenic mutation (also known as c.4612C>T), located in coding exon 13 of the BRCA1 gene, results from a C to T substitution at nucleotide position 4612. This changes the amino acid from a glutamine to a stop codon within coding exon 13. This mutation has been reported in multiple individuals and families with hereditary breast and ovarian cancer (HBOC) (Tartaglini E et al. Hum. Mutat., 1998;Suppl 1:S163-6; De Leon Matsuda ML et al. Int. J. Cancer, 2002 Apr;98:596-603; Young SR et al. BMC Cancer, 2009 Mar;9:86; Guan Y et al. Fam Cancer, 2015 Mar;14:9-18; Heramb C et al. Hered Cancer Clin Pract, 2018 Jan;16:3; Rebbeck TR et al. Hum Mutat, 2018 05;39:593-620; Singh J et al. Breast Cancer Res Treat, 2018 Jul;170:189-196; Carter NJ et al. Gynecol Oncol, 2018 12;151:481-488; Wang N et al. Chin J Cancer Res, 2020 Apr;32:149-162). This mutation has also been reported with a carrier frequency of 0.00013 in 7636 unselected prostate cancer patients and absent in 12366 male controls of Japanese ancestry (Momozawa Y et al. J Natl Cancer Inst, 2020 04;112:369-376). Of note, this alteration is also designated as 4731C>T and Q1538X in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000420125 SCV001133591 pathogenic not provided 2019-05-02 criteria provided, single submitter clinical testing This variant causes the premature termination of BRCA1 protein synthesis. It has been reported in in affected individuals with breast and/or ovarian cancer in the published literature (PMIDs: 9452076 (1998), 11920621 (2002), 25151137 (2015), 29339979 (2018) and 29470806 (2018)). Based on the available information, this variant is classified as pathogenic.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000048606 SCV001338294 pathogenic Hereditary breast ovarian cancer syndrome 2020-02-12 criteria provided, single submitter clinical testing Variant summary: BRCA1 c.4612C>T (p.Gln1538X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. The variant was absent in 251362 control chromosomes (gnomAD). c.4612C>T has been reported in the literature in multiple individuals affected with Hereditary Breast and Ovarian Cancer (e.g. Rebbeck_2018, DeLeonMatsuda_2002, Singh_2018). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six ClinVar submitters (evaluation after 2014) including one expert panel (ENIGMA) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Color Diagnostics, LLC DBA Color Health RCV000510121 SCV001348222 pathogenic Hereditary cancer-predisposing syndrome 2020-01-15 criteria provided, single submitter clinical testing This variant changes 1 nucleotide in exon 14 of the BRCA1 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of BRCA1 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic.
Baylor Genetics RCV000077579 SCV004212689 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2023-10-22 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000077579 SCV000109382 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2012-05-01 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000077579 SCV000145129 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2002-05-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.